Compare Remitly Global Inc (RELY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Remitly Global Inc vs BIO-TECHNE Corp — how do they compare? Remitly Global Inc trades at $24.13 (market cap $4.98B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 2.3× Remitly Global Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Remitly Global Inc for 53 Days and BIO-TECHNE Corp for 64 Days on average.
| RELY | TECH | |
|---|---|---|
Market Cap | $4.98B | $11.36B |
Volume | 3,501,150 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $26.92 | $72.61 |
52-Week Low | $12.20 | $43.31 |
Typical Hold Time | 53 Days | 64 Days |
Enterprise Value | $4.34B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELY trades at $23.52, up 2.57% today, with a bullish technical signal from moving averages. The company demonstrates strong fundamental momentum, with revenue growing from $654M in 2022 to $1.64B in 2025 and achieving profitability with net income of $67.93M. Recent Q2 2026 earnings significantly beat expectations, and positive news highlights partnerships and growth under new leadership.
The outlook is positive, supported by robust revenue growth, expanding profit margins, and a strong analyst consensus. Key risks include execution in a competitive digital payments space and market volatility. With a consensus price target of $30.50, representing significant upside, the stock presents a compelling opportunity for growth-oriented investors, though its current RSI suggests it may be overbought in the short term.
TECH trades at $72.46, near its 52-week high of $72.70, with a slight daily decline of 0.1%. The stock shows a bullish technical signal from moving averages, while oscillators are neutral. Recent earnings have been mixed, with a Q2 2026 beat but a Q1 miss. The company maintains strong gross margins of 65.77%, though net income margin has compressed to 14.97% in 2025 from 24.6% in 2022. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The pending acquisition at $73.00 offers a clear near-term upside of about 0.7% from the current price, limiting downside risk. However, execution risks remain until deal closure, and profitability pressures pose concerns for standalone operations. Analyst consensus is divided with 46% Buy and 54% Hold ratings, reflecting cautious optimism amid transition uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
